ストックスクリーナーアプリを入手
2.38
3.03%
0.07
アフターアワーズ：
2.40
0.02
+0.84%
前日終値:
$2.31
開ける：
$2.27
24時間の取引高:
1.82M
Relative Volume:
0.80
時価総額：
$116.33M
収益：
-
当期純損益:
$-67.68M
株価収益率:
-1.3757
EPS:
-1.73
ネットキャッシュフロー:
$-54.24M
1週間 パフォーマンス:
-15.60%
1か月 パフォーマンス:
+5.31%
6か月 パフォーマンス:
-71.43%
1年 パフォーマンス:
-88.81%
1日の値動き範囲:
$2.23
$2.51
1週間の範囲:
$2.17
$2.80
52週間の値動き範囲:
$1.76
$26.35
Cabaletta Bio Inc Stock (CABA) Company Profile
CABA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.38 | 116.33M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-02-05 | 開始されました | Jefferies | Buy |
| 2023-11-29 | 開始されました | William Blair | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | Stifel | Buy |
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-07-18 | 開始されました | Guggenheim | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-01-08 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-19 | 開始されました | Cowen | Outperform |
| 2019-11-19 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Cabaletta Bio Inc (CABA) 最新ニュース
Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities By Investing.com - Investing.com South Africa
Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities - Investing.com
Cabaletta Bio (NASDAQ:CABA) Lowered to "Inline" Rating by Evercore ISI - MarketBeat
Wells Fargo Downgrades Cabaletta Bio (CABA) - MSN
Charles Schwab Investment Management Inc. Raises Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
Cabaletta Bio (NASDAQ:CABA) Downgraded by Wells Fargo & Company to Equal Weight - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces pivotal moment - Investing.com
Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? - Simply Wall St
Point72 Asset Management L.P. Makes New $3.15 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Jennison Associates LLC Reduces Stake in Cabaletta Bio Inc - GuruFocus.com
PRUDENTIAL FINANCIAL INC's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
Walleye Capital LLC Acquires 212,025 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024 - MSN
Weekly Analysts’ Ratings Updates for Cabaletta Bio (CABA) - Defense World
Unusually active option classes on open December 2nd - TipRanks
Cabaletta Bio (NASDAQ:CABA) Raised to Strong-Buy at TD Cowen - Defense World
Cabaletta Bio Sees Unusually High Options Volume (NASDAQ:CABA) - MarketBeat
US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode - Benzinga
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives $27.30 Consensus PT from Analysts - MarketBeat
Caballeta Bio Shares Surge The Most In 23 Months In A Single Day As It Unveils Plan To Meet FDA By 2025 For Systemic Sclerosis Drug Trial - Benzinga
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 - MSN
Cabaletta Bio’s CAR-T CABA-201 Effects Clinical Responses in Autoimmune Diseases - CGTLive™
Cabaletta Bio to Participate in Upcoming Investor Conferences in December - The Manila Times
2 Penny Stocks That Wall Street Predicts Will Soar 306% To 1,183% In 2025 - Barchart
2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025 - Inkl
Cabaletta Bio Inc (CABA-Q) QuotePress Release - The Globe and Mail
Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 - MSN
Cabaletta Bio, Inc. Set to Engage at Key Investor Conferences - MSN
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN
Cabaletta Bio shares retain Buy rating as H.C. Wainwright sees robust treatment effect - Investing.com
Cabaletta reports promising autoimmune therapy results By Investing.com - Investing.com Australia
Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times
Cabaletta reports promising autoimmune therapy results - Investing.com
Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright - Defense World
Inflammatory Myositis Treatment Market: Segmentation Trends, - openPR
Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat
Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK
Cabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Cabaletta Bio price target lowered to $12 from $20 at Wells Fargo - TipRanks
Cabaletta Bio Inc. (CABA) Quarterly 10-Q Report - Quartzy
T. Rowe Price Investment Management, Inc. Reduces Stake in Cabal - GuruFocus.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target - Investing.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target By Investing.com - Investing.com UK
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio Inc (CABA) 財務データ
収益
当期純利益
現金流量
EPS
Cabaletta Bio Inc (CABA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | See Remarks |
Jan 19 '24 |
Sale |
19.59 |
11,000 |
215,439 |
20,000 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):